alexa Abstract | Evaluating the use of Ertapenem (Invanz®) in a Hospital System-Epidemiologic and Financial Implications

Research & Reviews: Journal of Hospital and Clinical Pharmacy
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access


Purpose: Carbapenems may represent the last effective antibiotics for many multi-drug-resistant gram-negative infections, warranting judicious use in order to curb resistance. In an effort to examine use of a last-line antimicrobial agent and minimize antimicrobial expenditures, ertapenem utilization and wholesale acquisition cost (WAC) expenditures were described at three facilities in San Antonio, Texas. Methods: This multicenter, retrospective study included 1,448 patients who received ertapenem between July 1, 2013 and December 31, 2013. Patients were analyzed based on number of doses, treatment indication, prescribing physician’s specialty, and available microbiology lab results. WAC information was obtained from Amerisource Bergen and RED BOOK for projection of cost savings with an alternative therapeutic option (cefazolin+metronidazole) from the organizational perspective. Results: In total, 3,301 doses of ertapenem were administered, representing an average monthly use of 51.1 doses per 1,000 patient days and a WAC of $270,259 ($81.87/day). Internal medicine practitioners were responsible for the highest utilization, with 1,138 doses (34%) administered during the study period. General surgery, colorectal surgery, emergency medicine, and family medicine followed, with 480 (15%), 413 (13%), 414 (13%), and 290 (9%) ertapenem doses administered, respectively. By comparison, use of cefazolin+metronidazole in the study population resulted in an estimated WAC of $29,808 ($9.03/day). This represented a potential cost savings of $240,451. Conclusion: Analysis of ertapenem utilization at three regional hospitals over a 6-month period revealed substantial usage, which may negatively influence local resistance patterns. Additionally, use of cefazolin+metronidazole offers a noteworthy cost-savings potential.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Andrew Delgado*, Maren C. Cowley, Gerard W. Gawrys, Bryson M. Duhon, Jim M. Koeller


Carbapenems, Ertapenem, Intraabdominal infections, Clinical Pharmacy, Patient care, Safe Drug Therapy

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version